Skip to main content

Table 6 Number and percentage of children with a systemic adverse event on days 0 and 42 in the safety set

From: Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro®) and a varicella vaccine (VARIVAX®) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial

 

IM group

N= 3741

SC group

N= 3761

 

Number of subjects (%)2

Systemic adverse event

295 (78.9)

295 (78.5)

Vaccine-related systemic adverse event

156 (41.7)

156 (41.5)

   Related to M-M-RvaxPro

153 (40.9)

149 (39.6)

   Related to VARIVAX

121 (32.4)

125 (33.2)

Measles-like rash3

11 (2.9)

10 (2.7)

Mumps-like illness

0

1 (0.3)

Rubella-like rash3

10 (2.7)

10 (2.7)

Varicella-like rash3

2 (0.5)

12 (3.2)

  1. (IM group, both vaccines administered by the intramuscular route; SC group, both vaccines administered by the subcutaneous route)
  2. 1Number of vaccinated subjects according to the protocol and the actual route of administration
  3. 2 Number (and percentage) of subjects presenting the event at least once
  4. 3Non-injection site rash